Best of ASCO - 2014 Annual Meeting

 

Welcome

Tissue-Based Biomarkers

Developmental Immunotherapy and Tumor Immunobiology

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A landscape analysis of immunotherapy-related biomarkers across solid tumors.

Lara Ann Kujtan

e14268

A multiplex immunofluorescence assay to assess immune checkpoint inhibitor-targeted CD8 activation and tumor colocalization in FFPE tissues.

Tony Navas

2629

Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer.

Martin D. Berger

2633

Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab.

Michael E. Hurwitz

2623

Biomarkers of Chinese advanced cancer patients based on real-world data: Actionable genomic alterations and tumor mutational burden.

HaiTao Wang

e14280

BRCA 1/2 mutations in high-grade serous ovarian cancer (HGS-OC) patients of three Latin American countries: Report of 412 cases.

Juan Molina

e14288

Breast cancer with insertion or deletion exhibits the immunogenic phenotype.

Yongmei Yin

2622

Breast MRI as a radiomic biomarker of immune enrichment in HER2+ breast cancer.

Laura Kennedy

e14281

Cancer-testis gene-expression features in various tumors.

Kristina I. Soldatova

e14260

Changes in tumor mutational burden in serially biopsied non-small cell lung cancer.

James W. Smithy

e14286

Coexpression patterns of IDO-1, PD-L1 and EGFR in non-small cell lung cancer.

Weili Wang

e14279

Comparison between whole exome sequencing (WES) and single nucleotide polymorphism (SNP)-based tumor mutation burden analysis.

Kirsten Timms

2634

Comparison of biomarkers among 34,855 GI cancer samples show heterogeneity of tumor types.

Shaheenah S. Dawood

e14287

Comprehensive analysis of immune indicators provides prognostic markers for early stage non-small cell lung cancer.

Xiao Ding

e14276

Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).

Matthew Labriola

e14259

Correlation between K-RAS mutant subsets, TP53 mutation, and PD-L1 status in non-small cell lung cancer (NSCLC).

Nagla Fawzy Abdel Karim

e14272

Defining tissue requirements for a reliable detection of tumor mutational burden (TMB) in clinical FFPE samples.

Hans-Ulrich Schildhaus

e14265

Development of a PD-L1 multiplex immunofluorescence assay with advanced visual analysis for understanding the tumor microenvironment.

Sean Downing

e14283

Electrostatic human leukocyte antigen-neoantigen interactions and durable benefit in non-small cell lung cancer patients treated with immunotherapy.

Amy Lauren Cummings

2635

Evaluation of combined biomarkers for tumor response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC).

Hayat Oum El Kheir Ramdani

e14269

Evaluation of TMB estimates for the prediction of response to immune checkpoint blockage.

Jan Budczies

2632

Frequency of discordance in programmed death ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: A systematic review and meta-analysis.

Chia Ching Lee

e14290

Immune checkpoint inhibitor response in tumors with LRP1B variants.

Jason Zhu

e14291

Impact of biopsy methodology on biomarker testing in NSCLC in EU5.

Christophe Homer

e14264

Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC.

Sushma Jonna

2627

Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model.

Kirstin Perdrizet

2620

NSCLC mutation frequency in the central American and Caribbean region.

Luis Corrales-Rodriguez

e14278

Overestimation of tumor mutational burden (TMB) using algorithms compared to germline subtraction.

Kaushal Parikh

2621

PD-L1 expression in soft tissue sarcomas and its prognostic implication.

Mohamed Reda Kelany

e14261

Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.

Khanh Tu Do

2619

Preliminary effects on the innate immune system with the combination of cetuximab and durvalumab in metastatic/ relapsed head and neck squamous cell carcinoma in a phase II trial.

Shuchi Gulati

e14273

Prognostic implications of PD-L1 expression in breast cancer at the protein and mRNA levels.

Alexios Matikas

e14284

Prognostic value of Tfh-like cells in breast cancer.

Linxiaoxi Ma

e14285

Quantitative MHC II protein expression levels in tumor epithelium to predict response to the PD1 inhibitor pembrolizumab in the I-SPY 2 Trial.

Julia Dianne Wulfkuhle

2631

Surface programmable activation receptor (SPAR) cell platform for the rapid detection of melanoma-specific biomarkers.

Joel Lwande

e14263

The consensus Immunoscore adapted to biopsies in patients with locally advanced rectal cancer: Potential clinical significance for a “Watch and Wait” strategy.

Carine El Sissy

2628

The role of different TGFβ signatures in predicting outcome in high grade serous ovarian carcinoma.

Haider Mahdi

e14262

Tissue immune response in epithelial ovarian carcinoma.

Jon Henriksen

2625

TMB standardization by alignment to reference standards: Phase II of the Friends of Cancer Research TMB Harmonization Project.

Diana M. Merino

2624

Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC.

Emily Castellanos

2630

Tumor mutational burden (TMB) profile of K-RAS/TP-53 co-mutation in metastatic non-small cell lung cancer (m-NSCLC).

Abdul Rafeh Naqash

2626

Tumor mutational burden assessed by a targeted NGS assay to predict clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.

Sacha Rothschild

e14266

Utilization of novel highly multiplexed immunofluorescence microscopy technology to understand immunological tumor microenvironments in small cell lung carcinoma patients receiving combination PD-L1 and PARP inhibition therapy.

Christopher Julius Trindade

e14289